Free Trial
NASDAQ:NOTV

Inotiv Q2 2025 Earnings Report

Inotiv logo
$2.03 +0.05 (+2.53%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.02 0.00 (-0.25%)
As of 05/2/2025 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inotiv EPS Results

Actual EPS
N/A
Consensus EPS
-$0.23
Beat/Miss
N/A
One Year Ago EPS
N/A

Inotiv Revenue Results

Actual Revenue
N/A
Expected Revenue
$123.97 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inotiv Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Inotiv Earnings Headlines

Lake Street Remains a Buy on Inotiv (NOTV)
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Inotiv Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inotiv? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inotiv and other key companies, straight to your email.

About Inotiv

Inotiv (NASDAQ:NOTV) provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

View Inotiv Profile

More Earnings Resources from MarketBeat